Merck KGaA stock (DE0006599905): Latest developments and business overview

Merck KGaA, the German healthcare and chemicals group, continues to advance in life sciences and electronics amid ongoing market volatility. US investors track its Nasdaq-listed subsidiary and global exposure.

Merck KGaA maintains its position as a diversified player in healthcare, life sciences, and electronics. The Darmstadt-based group reported steady progress in its core segments during its most recent quarterly update published on April 25, 2025, for the first quarter period ending March 31, 2025, showing resilient demand in biopharma tools and display materials, according to Merck IR as of 04/25/2025.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Merck KGaA
• Sector/industry: Healthcare, Life Sciences, Electronics
• Headquarters/country: Darmstadt, Germany
• Core markets: Europe, US, Asia
• Key revenue drivers: Biopharma tools, cancer therapies, semiconductors
• Home exchange/listing venue: Xetra (MRK.DE)
• Trading currency: EUR

Merck KGaA: core business model

Merck KGaA operates through three main pillars: Healthcare, Life Science, and Electronics. The Healthcare division focuses on innovative therapies, particularly in oncology and neurology, with products like Mavenclad for multiple sclerosis. Life Science provides tools and services for biotech research and manufacturing, serving pharmaceutical companies globally. Electronics supplies materials for semiconductors and displays, capitalizing on tech sector growth. This diversified model reduces sector-specific risks, with Q1 2025 sales up 1% to €5.1 billion as reported in the earnings release dated April 25, 2025, from Merck IR as of 04/25/2025.

The company's strategy emphasizes R&D investment, allocating €1.2 billion in Q1 2025, or 12% of sales, to pipeline advancement. Merck KGaA distinguishes itself from US-based Merck & Co (MRK) via its European roots and broader portfolio beyond pharmaceuticals.

Main revenue and product drivers for Merck KGaA

Life Science generated €2.1 billion in Q1 2025 sales, driven by process solutions for biologics production amid rising demand for mRNA and cell therapies. Healthcare contributed €1.9 billion, led by oncology drugs like Tepmetko and the immunology portfolio. Electronics saw €1.1 billion, benefiting from OLED and semiconductor materials for consumer electronics and AI chips, per the April 25, 2025 quarterly report from Merck IR as of 04/25/2025.

Key products include Milli-Q water purification systems in Life Science and deposition materials in Electronics. Geographic revenue splits show 30% from North America, underscoring US market importance for American investors.

Industry trends and competitive position

The life sciences tools market grows at 8% CAGR through 2030, per Gartner 2024 report, where Merck KGaA holds top-tier share alongside Thermo Fisher. In oncology, it competes with Roche and Bristol Myers, but niche MS therapies provide stability. Electronics benefits from semiconductor upcycle, with peers like DuPont.

Merck KGaA's 2025 EBITDA margin target of 20-22% reflects operational efficiency gains from digitalization and site optimizations announced in the 2024 annual report published March 2025.

Why Merck KGaA matters for US investors

US investors access Merck KGaA via OTC (MKKGY) or its subsidiary MilliporeSigma, a key US life sciences player. The group derives 30% revenue from North America, exposed to US biotech boom and tech manufacturing resurgence via CHIPS Act incentives. Its €2 billion US investments since 2020 enhance appeal amid supply chain localization trends.

Recent financial performance

Full-year 2024 sales reached €20.6 billion, flat YoY but with 5% organic growth excluding FX, as per annual results on March 5, 2025, from Merck IR as of 03/05/2025. Net profit rose 15% to €2.9 billion, supported by cost controls. Order intake in Life Science surged 10%, signaling pipeline strength.

Conclusion

Merck KGaA demonstrates resilience across its diversified segments, with solid Q1 2025 results and strategic investments positioning it for biopharma and electronics growth. US exposure via key markets and listings offers relevant opportunities amid global trends. Investors monitor upcoming earnings and pipeline milestones for further insights into performance.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.